Clear Search

Showing 4 results for “Doria A”.

October 2025

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update

Ann Rheum Dis 2025;0:1−16 Doi: 10.1016/j.ard.2025.09.007

The updated EULAR recommendations provide evidence- and expert-based consensus on the management of SLE with kidney involvement, adjusted for severity, and taking into consideration long-term efficacy, safety, cost, and local availability of drugs. Fanouriakis A et al. updated the 2019 EULAR/ ERA-EDTA recommendations for the management of SLE with kidney involvement, taking into consideration emerging evidence and recent developments in the field.

more…

August 2025
April 2025

Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumab

Rheumatol (Oxford), 2025 DOI: 10.1093/rheumatology/keaf215. Epub ahead of print

Depascale et al. used unsupervised machine learning to identify three SLE endotypes based on B cell immunophenotyping and serological profiles. Belimumab was most effective in patients with transitional and naïve B cell enrichment (Cluster 2), where it significantly increased the likelihood of achieving sustained LLDAS and DORIS remission.

more…

November 2023

EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update

Ann Rheum Dis 2023;83(1):15–29 DOI: 10.1136/ard-2023-224762

 The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

more…